Pharsight

Natazia generic

Natazia is an oral contraceptive drug owned by Bayer Healthcare. The active ingredients of Natazia are Dienogest and Estradiol Valerate. Natazia was first approved for market use on 06 May, 2010.

When will Natazia generic be available?

The generic versions of Natazia are likely to hit the market after 30 January, 2028. This timeline is determined by the last expiring patent, US8153616, which is set to expire on this date. The earlier patent, US8071577, will expire earlier on 2026-05-13.

Natazia uses

Natazia is used for the treatment of heavy menstrual bleeding in women without organic pathology who elect to use an oral contraceptive as their mode of contraception. It is also used for the prevention of pregnancy.

Natazia patent expiration

Natazia is protected by 2 patents. The most current patent, 'Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same' (US8153616), will expire on 2028-01-30, which is the expected release date of Natazia generic. The earlier patent 'Multi-phase contraceptive preparation based on a natural estrogen' (US8071577) is expiring on 2026-05-13. Below are the details of the patents:

EPO Oppostions filed on Natazia

Natazia dosage

Want to ask something?